Hepatitis C virus–HIV coinfection

Hepatitis C virus–HIV coinfection is a clinically consequential relationship between two bloodborne viral infections whose shared routes of transmission create overlapping populations and whose interaction complicates liver, kidney, and survival outcomes. The central pattern is asymmetric: HIV clearly accelerates HCV-related liver disease, whereas the independent effect of HCV on HIV progression and on the full range of renal lesions remains more difficult to establish. The evidence therefore combines strong associations—especially for cryoglobulinemic membranoproliferative glomerulonephritis—with substantial uncertainty about other immune-complex diseases and about the benefits of specific anti-HCV treatment.

Definition and Epidemiologic Setting

Hepatitis C virus–HIV coinfection occurs when both viruses are present in the same patient. The book estimates that approximately 30% of people infected with HIV are also infected with HCV, although reported prevalence varies from less than 10% to more than 70%. Such variation reflects the risk profile of the population: people with HIV who use illicit intravenous drugs or practice unsafe and promiscuous sex occupy the higher ranges, while those who acquired HIV through other routes generally have lower rates of HCV coinfection.

The overlap is explained by shared transmission routes, but the order of infection is not uniform. Intravenous drug users typically acquire HCV before HIV, whereas HIV commonly precedes HCV in men who have sex with men. This sequence matters clinically because the first infection establishes a background of immune disturbance or viral replication before the second virus appears, producing a relationship that cannot be understood simply as two independent diagnoses.

The two infections must also be distinguished diagnostically from antibody evidence alone. Active chronic HCV infection requires both anti-HCV positivity and detectable HCV RNA for more than six months; antibody positivity without RNA indicates resolved rather than active infection. In a patient with HIV, that distinction determines whether HCV represents an ongoing hepatic and extrahepatic threat and whether viral disease should be evaluated for treatment.

Hepatic Interaction and Overall Prognosis

The clearest interaction runs from HIV to HCV-related liver disease. HIV accelerates progression of HCV-induced liver injury, principally through increased fibrosis. Morbidity and mortality caused by HCV-related liver disease are consequently higher in coinfected patients than in patients with HCV infection alone. The proposed mechanisms include the immunosuppressive effect of HIV and increased production of proinflammatory cytokines, which together hasten progression toward end-stage liver failure.

The severity of the hepatic course extends to malignancy. Some studies suggest that hepatocellular carcinoma appears at a younger age in coinfected patients and carries a worse prognosis than in patients with HCV alone. Antiretroviral therapy has a beneficial effect on progression of liver disease, but this benefit is not without management difficulty: pre-existing HCV-related chronic liver disease may increase the hepatotoxicity of some antiretroviral agents. Treatment therefore has to balance suppression of HIV against the vulnerability of an already injured liver.

The reverse influence—whether HCV worsens HIV—is less settled. Some studies reported that HCV infection adversely affects progression to a new AIDS-defining illness or death, while others did not reproduce those findings. HCV viral load may account for part of the disagreement, because a clear correlation has been observed between higher HCV viral load and the risk of progression to AIDS and death in people with HIV. The relationship is thus clinically serious but not reducible to a single uniform effect in every cohort.

Renal Disease and Cryoglobulinemic Injury

Both viruses can produce renal complications, and people with coinfection may develop the spectrum of kidney disease associated with either infection. HIV-associated nephropathy remains an important diagnosis, but HIV infection is also associated with immune-complex glomerulonephritides, including membranoproliferative glomerulonephritis, IgA nephropathy, non-collapsing focal segmental glomerulosclerosis, membranous nephropathy, and lupus-like glomerulonephritis. Hypertensive nephrosclerosis, diabetic nephropathy, and reduced renal function resembling the chronic kidney disease of older populations are also increasingly recognized.

The characteristic HCV-associated renal lesion is cryoglobulinemic membranoproliferative glomerulonephritis. In coinfected patients, many reported cases of membranoproliferative glomerulonephritis include circulating cryoglobulins and are therefore more plausibly interpreted as HCV-related cryoglobulinemic disease than as a nonspecific manifestation of HIV. Mixed cryoglobulinemia may produce skin purpura, arthralgias, Raynaud phenomena, and, in severe cases, skin necrosis or pulmonary hemorrhage. Laboratory findings can include hypocomplementemia, increased rheumatoid factor, and circulating type II cryoglobulins.

The renal biopsy pattern is correspondingly distinctive. It may show mesangial proliferation, double contours of glomerular capillaries, IgG, IgM, and C3 deposits on immunofluorescence, subendothelial electron-dense deposits, cryoglobulin thrombi occluding capillary lumens, and occasional vasculitis of extraglomerular vessels. Clinical expression ranges from persistent non-nephrotic proteinuria and microscopic hematuria with preserved renal function to nephrotic syndrome, macroscopic hematuria, and acute renal failure.

HCV may nevertheless contribute to renal disease beyond cryoglobulinemic membranoproliferative glomerulonephritis, but the evidence is insufficient to define its role. Coinfected patients can develop several immune-complex lesions, and the pathogenic contribution of HCV in IgA nephropathy, focal segmental glomerulosclerosis, membranous nephropathy, or lupus-like glomerulonephritis remains uncertain. The difficulty is compounded by the aggressive clinical presentation of many HIV-associated glomerular diseases and by the scarcity of dedicated clinical and investigative information.

Outcomes and Treatment Implications

Reported patient and renal survival in glomerular disease among coinfected patients has been very poor, although the historical evidence is shaped by limited use of antiretroviral therapy. In the only cited series in which most patients received antiretroviral treatment, prognosis appeared substantially better than in earlier reports. On that basis, antiretroviral therapy should be prescribed for patients with HIV and glomerular disease regardless of whether HCV coinfection is present.

The effect of HCV coinfection is not uniform across stages of kidney disease. In a study of HIV-infected women, 35% were HCV-seropositive. Among women who already had chronic kidney disease, defined by an estimated glomerular filtration rate below 60 ml/min/1.73 m2, HCV seropositivity independently predicted a more rapid decline in renal function. Among women with normal renal function, however, coinfection did not influence progression of renal disease. This contrast suggests that HCV may be particularly consequential once renal vulnerability is established rather than acting as an equally strong accelerator at every stage.

Specific anti-HCV therapy remains less firmly grounded than treatment directed at HIV. Available recommendations and studies have generally focused on HCV-induced liver disease rather than renal disease in coinfected patients, and information about the results of anti-HCV therapy or immunosuppressive agents in this setting is very limited. The broader management context nevertheless requires assessment of active HCV infection, liver fibrosis, and extrahepatic disease, including cryoglobulinemia-associated vasculitis. Noninvasive fibrosis methods such as biochemical scores and FibroScan can reduce the need for liver biopsy and permit repeated follow-up, while treatment decisions must account for viral status, organ injury, and drug toxicity.

Transmission, Dialysis, and Evidence Limits

The coinfection relationship also intersects with medical environments in which HCV transmission has historically occurred. Hemodialysis patients were recognized as a high-risk group after HCV was identified as the main cause of non-A non-B hepatitis, and the early high prevalence reflected both transfusion exposure and ongoing nosocomial transmission within dialysis units. As blood screening improved, the risk of post-transfusion HCV infection fell from about 0.5% per blood unit in the 1980s to approximately 0.0001%, or one case per million blood units, in the United States. Attention consequently shifted toward infection-control failures in dialysis settings.

Molecular virology strengthened that conclusion. Phylogenetic analyses identified clusters of closely related HCV isolates among patients treated in the same hemodialysis units, using variable genomic regions as fingerprints of viral isolates or quasispecies. A systematic review found that all twenty examined studies suggested failures in infection-control procedures as the probable cause of new cases, although none conclusively established a specific transmission route. In eighteen of the twenty studies, some or all newly infected patients did not share a dialysis machine with the source patient, indicating that the internal machine circuit played, at most, a small role.

These findings led the KDIGO workgroup not to recommend dedicated dialysis machines for HCV-infected patients and not to recommend isolation in a separate ward as an alternative to strict infection-control procedures. The evidence favored hand hygiene, gloves, disposal of single-use items, disinfection of nondisposable equipment and contaminated surfaces, appropriate dialyser-reuse procedures where reuse was unavoidable, waste management, and regular observational audits. The broader lesson for coinfected populations is that transmission risk is shaped not only by host and pathogen but also by the organization of care.

Overall, Hepatitis C virus–HIV coinfection is defined by both interaction and uncertainty. The evidence is strongest that HIV worsens HCV-related fibrosis, liver failure, and possibly hepatocellular carcinoma, and that HCV is the likely driver of cryoglobulinemic membranoproliferative glomerulonephritis in many coinfected patients. Elsewhere, attribution remains contested, survival data are influenced by changing antiretroviral practice, and specific anti-HCV renal evidence is sparse. The relationship therefore demands integrated virologic diagnosis, hepatic and renal assessment, infection-control vigilance, and treatment decisions that recognize both the measurable burden and the limits of current knowledge.